InvestorsHub Logo
Followers 468
Posts 26892
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 130

Friday, 05/06/2011 9:58:11 AM

Friday, May 06, 2011 9:58:11 AM

Post# of 604
7:40AM On The Wires (WIRES) :

Rigel Pharmaceuticals, Inc. (RIGL) announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 clinical trials. Pfizer (PFE) is returning full rights to the R343 program as a result of its decision to exit the allergy and respiratory therapeutic area within R&D. Rigel is evaluating the details of R343's development to date and expects to design a Phase 2 clinical trial with R343 later this year.


surf's up......crikey



Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RIGL News